Navigation Links
Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo
Date:2/22/2011

SEATTLE, Feb. 22, 2011 /PRNewswire/ -- Omeros Corporation (Nasdaq: OMER) today announced that its exclusive license to phosphodiesterase 7 (PDE7) inhibitors from Daiichi Sankyo Co., Ltd. has been amended to include addiction and compulsive disorders in the field of use. Omeros' PDE7 program was founded on the Company's discovery of a previously unknown link between PDE7 and any movement disorder, such as Parkinson's disease.  Omeros believes that it also is the first to link PDE7 to any addiction or compulsive behavior, and is now advancing PDE7 inhibitors for the treatment of these as well as movement disorders. Omeros is collaborating on this program with both the National Institute on Drug Abuse (NIDA) and The Michael J. Fox Foundation.

"We are pleased to announce our agreement with Daiichi Sankyo and the additional therapeutic focus of our PDE7 program," stated Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "From the advanced Daiichi compounds we have already selected a clinical candidate, and we expect that addiction will provide us with a faster and less expensive development pathway for our PDE7 program. We are collaborating with NIDA on additional studies that will evaluate our compounds in addiction, and we look forward to working with NIDA to advance this program through the clinic."

PDE7 appears to modulate the dopaminergic system, which plays a significant role in regulating both movement and addiction. Omeros believes that PDE7 inhibitors could be effective therapeutics for the treatment of movement disorders as well as addiction and compulsive disorders. Omeros has shown in animal models of cocaine addiction that PDE7 inhibitors reduce cocaine self-administration, inhibit relapse induced by cues and stress, and facilitate drug abstinence in previously addicted animals. Importantly, no effect on normal feeding was observed
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Announces Publication of Data From Antifibrinolytic Program
2. Omeros Licenses Novel Antifibrinolytic Agents
3. Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy
4. Omeros to Host Conference Call Monday, October 25 at 4:00 p.m. ET To Provide Corporate Update
5. Omeros to Present at the BioCentury NewsMakers Conference
6. Omeros Enrolls First Patient in Phase 2b Clinical Trial Evaluating OMS302 in Patients Undergoing Cataract Surgery
7. Omeros Successfully Unlocks Orphan GPCRs
8. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
9. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
10. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
11. Daniel K. Spiegelman Elected to Board of Directors of Omeros
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015  The Partnership to Fight Chronic Disease (PFCD) released ... care leaders and a new study analyzing the impact of increased ... a nationwide coalition working to educate policy makers and the public ... Capitol was focused on how the Iowa ...
(Date:1/23/2015)... Fla. and DUBLIN , Jan. ... the agreement with KRS Global Biotechnology, Inc. for the compounding, ... be compounded for shipment in the United States ... FDA approved Outsourcing Facility capable of compounding naltrexone tablets in ...
(Date:1/23/2015)... , Jan. 23, 2015  iMD Companies, Inc. (ICBU) has ... increase market share and grab a foothold in the hydroponic, ... production capabilities and a presence in the sector, and recently ... the growth of hemp and medical marijuana, iMD is committing ...
Breaking Medicine Technology:New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2
... , WILMINGTON, Del., Dec. 8 AstraZeneca (NYSE: ... Medicare Part D prescription savings program will no longer pay ... http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO ) , Prescriptions also now will ... changes to the AZ&Me(TM) Prescription Savings program for people with ...
... , PITTSBURGH, Dec. 8 Mylan Inc. (Nasdaq: ... has entered into settlement and license agreements with Wyeth, now ... (ER) Capsules, 37.5 mg, 75 mg and 150 mg, the ... major depressive disorder. , Pursuant to the license agreement, Mylan ...
Cached Medicine Technology:AstraZeneca Medicare Part D Patient Assistance Program No Longer Requires Co-Pays 2Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R) 2
(Date:1/22/2015)... a seasoned and trusted leader who consistently delivers trendy dresses ... it lead the wedding dress industry into the future. Today, ... the global market. , “The CEO of VogueQueen is uniquely ... continuing the goal of operational excellence and giving back to ...
(Date:1/22/2015)... 23, 2015 Angelweddingdress is a famous wedding ... its customers to follow it on Facebook, Twitter, and Pinterest. ... Day gift. Angelweddingdress draws a lottery every week. , Moreover, ... Feb. 28, 2015. Click Angelweddingdress homepage for more ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has ... View website of AngelWeddingDress.com to find more ... dresses online for a bridal party. AngelWeddingDress offers a ... them. Its maternity wedding dresses are specially designed for ...
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and ... Merchandise Show to bestow a Juvent Sports Achievement award ... Arlene McKitrick. The award commemorated and congratulated McKitrick for ... She won her first amateur tournament in 1979 and ...
(Date:1/22/2015)... 2015 Thousand of GranuFlo lawsuits ( ... its GranuFlo and NaturaLyte dialysis concentrates continue to move ... District Court, District of Massachusetts, Bernstein Liebhard LLP reports. ... has remanded a case filed by the state of ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4
... MAY 28 Family Health International announced today that ... from the Bill & Melinda Gates Foundation. The ... led by David C. Sokal, M.D., studying a novel ... Sokal,s project is one of 81 grants announced by ...
... Identify Developmental Delays and Promote GrowthNEW ORLEANS, May 28 ... - 11:30am , at 1315 Jefferson Highway , ... "Reach Out and Read " with Louisiana,s First Lady ... program. In this initiative, pediatricians encourage parents to read ...
... with a terminal illness, African-American seniors were two times ... life-prolonging treatments, according to a University of Pittsburgh study ... the Journal of General Internal Medicine . ... M.P.H., associate professor of medical, clinical and translational science ...
... owned subsidiary of sanofi-aventis U.S. LLC, has agreed to pay ... violated the False Claims Act by misreporting drug prices in ... Department announced today. ... that between 1995 and 2000, Aventis and its corporate predecessors ...
... Public/Private Partnership Launches at State Legislative Hearing TRENTON, N.J., ... that could cause grave harm to patient care in ... New Jersey Chamber of Commerce Foundation today announced a ... will have the nursing workforce it needs to meet ...
... Kyowa Hakko U.S.A., Inc. (Kyowa Hakko USA), the wholly ... has announced it has completed GRAS (Generally Recognized As ... Citicoline. Cognizin(R) is a branded form of Citicoline, a ... Citicoline provides an essential nutrient for cells -- ...
Cached Medicine News:Health News:Family Health International Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research Project Led by David Sokal, M.D. 2Health News:Family Health International Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research Project Led by David Sokal, M.D. 3Health News:Family Health International Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research Project Led by David Sokal, M.D. 4Health News:Ochsner Introduces Literacy Program to Promote Healthy Minds 2Health News:Blacks more likely to opt for life-sustaining measures at end of life 2Health News:Aventis Pharmaceutical to Pay U.S. $95.5 Million to Settle False Claims Act Allegations 2Health News:$22 Million Initiative Aims to Reverse New Jersey's Nurse Faculty Shortage, Avert Health Care Crisis 2Health News:$22 Million Initiative Aims to Reverse New Jersey's Nurse Faculty Shortage, Avert Health Care Crisis 3Health News:$22 Million Initiative Aims to Reverse New Jersey's Nurse Faculty Shortage, Avert Health Care Crisis 4Health News:$22 Million Initiative Aims to Reverse New Jersey's Nurse Faculty Shortage, Avert Health Care Crisis 5Health News:Kyowa Hakko USA Announces GRAS Self-Affirmation for Novel Brain Health Ingredient Cognizin(R) Citicoline 2
Intended for the quantitative determination of glucose in serum. Reaction: endpoint. Wavelength: 500 nm. Linearity: 500 mg/dL (27.8 mmol/L)....
Inorganic phosphorus reagent is used for the quantitative determination of inorganic phosphorus in human serum....
For the quantitative kinetic determination of amylase activity, using manual or automated procedures, in human serum and urine....
Intended for the quantitative determination of gammaglutamyl transferase activity in serum or plasma. Single vial, dry powder reagent. Readily soluble at room temperature. Reaction: Kinetic. Waveleng...
Medicine Products: